A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

NCT04620330 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
KRAS Activating Mutation

Interventions

DRUG: avutometinib (VS-6766)
DRUG: avutometinib (VS-6766) and Defactinib

Sponsor

Verastem, Inc.